Q2 2025 Traws Pharma Inc Earnings Call Transcript
Key Points
- Traws Pharma Inc (TRAW) has made significant progress in advancing its antiviral candidates, particularly Ratutrelvir for COVID-19, which is moving into phase 2 clinical studies.
- The company is actively engaging with regulatory authorities like BARDA and the FDA to include Tivoxavir marboxil in the national drug stockpile for influenza preparedness.
- Ratutrelvir is designed to be used without Ritonavir, making it a safer alternative for patients ineligible for PAXLOVID due to drug interactions.
- Traws Pharma Inc (TRAW) reported a substantial increase in revenue for the second quarter of 2025, primarily due to the recognition of deferred revenue from a terminated licensing agreement.
- The company has reduced its net loss significantly compared to the same period in 2024, reflecting improved financial management and strategic focus on high-potential programs.
- Traws Pharma Inc (TRAW) experienced a decrease in cash equivalents and short-term investments from $21.3 million at the end of 2024 to $13.1 million by June 30, 2025.
- The initiation of a phase 2 study for bird flu has been deferred due to low recruitment likelihood, impacting the timeline for Tivoxavir marboxil's development.
- Research and development expenses decreased, indicating potential scaling back of certain programs, particularly in oncology.
- The company faces challenges in finding an appropriate partner to advance its legacy oncology assets, which could delay potential revenue streams from these programs.
- Despite progress, the company still faces uncertainties related to the regulatory approval process and market competition for its antiviral candidates.
Ladies and gentlemen, thank you for standing by.
Welcome to the Traws Pharma Incorporated second quarter 2025 Financial results and business update call.
(Operator Instructions)
As a reminder, this call is being recorded today, August 14, 2025.
At this time I'd like to turn the call over to John Franz of Life Site Advisors.
Thank you, operator, and welcome everyone to Traws Pharma's second quarter 2025 financial results and business update conference call. This morning, Traws issued a press release reporting its second quarter 2025 financial results and provided a business update.
If you've not yet seen this press release, it is available in the investor relations section of the company's website.
Following my introduction, we will hear from Traws Interim Chief Executive Officer Dr. Iain Dukes; Chief Science Officer Dr. C. David Pauza; Chief Medical Officer Dr. Robert R. Redfield, and Interim Chief Financial Officer Charles Parker.
Before we begin, I'd like to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
